Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MPO | P05164 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 1/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8699875 | 1.00 | KDM4E (0.69) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL7593998 | 0.95 | KDM4E (0.63) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL30052868 | 0.91 | KDM4E (0.60) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL29378473 | 0.90 | KDM4E (0.65) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL18541537 | 0.90 | KDM4E (0.65) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL16317501 | 0.90 | KDM4E (0.65) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL9868659 | 0.90 | OPRM1 (0.66) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL29391520 | 0.90 | OPRM1 (0.66) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL31016727 | 0.89 | KDM4E (0.58) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL20375720 | 0.89 | KDM4E (0.64) | KDM4EMAPTMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| EP-4017281-A1 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021127701-A1 | PET FOOD COMPOSITIONS | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-20250380721-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250270512-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-20240390433-A1 | GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN AND USE AS A LIVE DELIVERY AND PRODUCTION SYSTEM | BIOMEDIT, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-5846942-A | Cholecystokinin antagonists, their preparation and therapeutic use | WARNER-LAMBERT COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-5593967-A | Cholecystokinin antagonists, their preparation and therapeutic use | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0547178-A4 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER LAMBERT CO (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0547178-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992004045-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| CN-1031025-A | NUTRITIVE EMULSION PREPARATION | OTSUKA PHARMA CO LTD (JP) | 1989-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | KDM4E 4553/4885MAPT 2206/4885MEN1 4546/4885 |
| US-20240390433-A1 | GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN AND USE AS A LIVE DELIVERY AND PRODUCTION SYSTEM | BLVRB, GLB1, GUSB | KDM4E 4205/4885MAPT 2156/4885MEN1 2725/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | KDM4E 2677/4885MAPT 2398/4885MEN1 2352/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | KDM4E 3456/4885MAPT 1252/4885MEN1 1814/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | KDM4E 3487/4885MAPT 2780/4885MEN1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.